Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with ...

It has been about a month since the last earnings report for Danaher (DHR). Shares have added about 2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the ...

Financial giants have made a conspicuous bearish move on Danaher. Our analysis of options history for Danaher (NYSE:DHR) revealed 14 unusual trades. Delving into the details, we found 28% of traders ...

Investing.com -- Moody’s Ratings has upgraded Danaher Corporation’s ratings, citing the company’s solid operating performance despite macroeconomic challenges. The credit rating agency raised ...

Danaher (DHR) shares have edged modestly higher over the past month, gaining about 7%. Investors seem to be weighing up recent performance and the company’s underlying growth trends as they look for ...

Danaher Corporation reported its third-quarter earnings for 2025, surpassing analyst expectations with an earnings per share (EPS) of $1.89, compared to the forecasted $1.72. The company’s revenue ...

Forbes contributors publish independent expert analyses and insights. As a brief overview, Danaher offers professional, medical, industrial, and commercial products within Life Sciences, Diagnostics, ...

Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion. Non-GAAP core revenue was flat compared to the ...

Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have ...

Andrew Kessel was a breaking news writer for Investopedia until October 2025. He previously covered markets for Proactive Investors, with a focus on small-cap stocks in fintech, healthcare, mining, ...